A Phase 1, First-Into-Human, Escalating Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04995274 After Administration Of Single Oral Doses To Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2011
At a glance
- Drugs PF 4995274 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
- 17 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 17 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.